Lantern Pharma Inc. disclosed a live demonstration of its withZeta.ai AI platform for rare cancer drug discovery on April 9, 2026, highlighting capabilities, market opportunity, and revenue strategy via presentation Exhibit 99.1.
Key takeaways
Conducted live demonstration of withZeta.ai multi-agentic AI co-scientist on April 9, 2026.
Presentation covers platform capabilities, commercial architecture, rare cancer market opportunity, and competitive positioning.
Outlined near-term revenue strategy and growth roadmap for withZeta.ai.
Replay available at specified Zoom link.
Item 7.01 and Exhibit 99.1 not deemed filed under Exchange Act Section 18.
Contains forward-looking statements on platform advantages, market opportunity, and commercialization risks.